Key Takeaways
- Truist Securities elevates Biogen from Hold to Buy, increasing price target from $190 to $235
- Rating enhancement precedes Phase 2 data release for Alzheimer’s candidate diranersen scheduled for July 14
- Shares advanced 1.3% to $201.63 during premarket activity on Monday
- Analyst firm incorporates risk-adjusted sales projections for lupus therapy litifilimab and felzartamab into valuation model
- Second quarter financial results, scheduled for July 29, not expected to significantly impact stock trajectory according to Truist
Truist Securities elevated Biogen (BIIB) from Hold to Buy on Monday, boosting its price objective to $235 from a previous $190. This new target suggests approximately 18% potential upside based on Friday’s closing price of $199.15.
Shares of Biogen advanced 1.3% to $201.63 during premarket activity. While the biotechnology stock has declined 7.8% over the current month, it maintains a 13% gain year-to-date, outperforming the S&P 500’s 11% advance.
The timing of this upgrade correlates with Biogen’s scheduled presentation Tuesday at the Alzheimer’s Association International Conference in London, where comprehensive Phase 2 results for experimental compound diranersen will be disclosed.
Back in May, Biogen revealed that diranersen failed to achieve its primary endpoint in Phase 2 testing. Despite this setback, the biotechnology firm maintains its commitment to advancing into Phase 3 trials, with Tuesday’s data presentation expected to provide rationale supporting this strategic decision.
Truist characterized its outlook on the stock as “increasingly constructive,” citing expectations that diranersen data could represent a significant positive catalyst. The investment firm identifies “attractive risk/reward” dynamics ahead of what it describes as “de-risking pivotal data readouts.”
Pipeline Beyond Alzheimer’s
Truist’s positive stance extends beyond diranersen alone. The firm highlighted a series of late-stage pipeline data releases anticipated over the coming two years as fundamental drivers of sustained value creation.
This encompasses a Phase 3 data release for lupus treatment litifilimab projected for Q4 2026 and felzartamab results in antibody-mediated rejection expected around mid-2027.
The analyst firm assigned 50% probability-adjusted peak revenue estimates of approximately $750 million for litifilimab and 65% probability-adjusted revenue of roughly $500 million for felzartamab in antibody-mediated rejection, alongside $260 million for primary membranous nephropathy applications.
These pipeline additions elevated Truist’s projected 2035 revenue forecast by roughly $1.5 billion, forming the foundation for the enhanced price target.
The firm contends that current market valuations fail to fully reflect the commercial opportunities within Biogen’s Alzheimer’s and immunology development programs.
Watch the Partner Too
Investors monitoring Biogen should also track Ionis Pharmaceuticals, a development collaborator. Ionis shares experienced a sharp decline last week following the unexpected failure of a cardiovascular drug developed with AstraZeneca in clinical testing.
Truist indicated it does not consider Biogen’s Q2 financial report, scheduled for July 29, as a significant catalyst for the stock.
Rather, the firm anticipates pipeline developments ā beginning with Tuesday’s diranersen data disclosure ā will shape investor sentiment throughout the coming quarters.
Biogen shares have gained 13% year-to-date in 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
